A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Ixekizumab (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms SPIRIT-H2H
- Sponsors Eli Lilly
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.
- 17 Aug 2017 Planned initiation date changed from 14 Aug 2017 to 28 Aug 2017.
- 01 Aug 2017 Planned End Date changed from 1 Mar 2019 to 21 Jun 2019.